Remodelin hydrobromide is primarily used in research settings for its ability to inhibit the enzyme N-acetyltransferase 10 (NAT10), which plays a role in nuclear architecture and gene expression. By targeting NAT10, it has been shown to improve nuclear shape abnormalities, making it a valuable tool in studying diseases associated with nuclear envelope defects, such as laminopathies and Hutchinson-Gilford progeria syndrome. It is also used to investigate cellular aging, chromatin organization, and DNA damage response pathways. Due to its role in reversing nuclear morphological defects, it holds potential as a lead compound in developing therapies for premature aging disorders and age-related conditions. Its application remains largely experimental and is not used clinically.